(Q43857255)

English

A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy

scientific article published in December 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 November 2017

A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy (English)

1 reference

Europe PubMed Central

27 November 2017

multiple sclerosis

0 references

author name string

O A Khan

1

1 reference

Europe PubMed Central

27 November 2017

A C Tselis

2

1 reference

Europe PubMed Central

27 November 2017

J A Kamholz

3

1 reference

Europe PubMed Central

27 November 2017

J Y Garbern

4

1 reference

Europe PubMed Central

27 November 2017

R A Lewis

5

1 reference

Europe PubMed Central

27 November 2017

R P Lisak

6

1 reference

Europe PubMed Central

27 November 2017

publication date

1 December 2001

1 reference

Europe PubMed Central

27 November 2017

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

27 November 2017

7

1 reference

Europe PubMed Central

27 November 2017

6

1 reference

Europe PubMed Central

27 November 2017

349-353

1 reference

Europe PubMed Central

27 November 2017

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

STREPTOMYCIN treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F135245850100700601

21 January 2018

Identifiers

10.1177/135245850100700601

1 reference

Europe PubMed Central

27 November 2017

1 reference

Europe PubMed Central

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43857255&oldid=2103935594"